The purpose of the invention is to maximize the efficacy of, minimize the incidence of side effects from, and improve the storage stability of eye drops that contain: a peptide (SSSR),the amino acid sequence of which is represented by Ser-Ser-Ser-Arg, or a pharmacologically acceptable salt thereof； and a peptide (FGLM), the amino acid sequence of which is represented by Phe-Gly-Leu-Met-NH 2 , or a pharmacologically acceptable salt thereof. The concentration ratio between the SSSR or a pharmacologically acceptable salt thereof and the FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of the SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3 % (w/v) and the concentration of the FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drops is maintained between 2.5 and 6.5.
